Flurbiprofen Pretreatment in Argon Laser Trabeculoplasty for Primary Open-Angle Glaucoma

Weinreb, Robert N.; Robin, Alan L.; Baerveldt, George; Drake, Michael V.; Blumenthal, Michael; Wilensky, Jacob T.

doi:10.1001/archopht.1984.01040031319016

Cited by 42 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Numerous researchers have used different presurgical pharmacological treatments to decrease the IOP rise by means of topical and/or systemic therapy. These include beta blockers, 6-8 pilocarpine, 9 clonidine, 10 dorzolamide, 11 iopidine, 12 corticosteroids, 13 nonsteroidal anti-inflammatory agents, 14,15 and carbonic anhydrase inhibitors. 16 The majority of these systemic treatments did not have the desirable therapeutic effects except for oral carbonic anhydrase inhibitors that are capable of preventing pressure rises in the treated patients.…”

Section: Introductionmentioning

confidence: 42%

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Pescosolido

Librando

Puzzono

et al. 2011

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 42%

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Pescosolido

Librando

Puzzono

et al. 2011

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The exact reason for the early IOP elevation remained unknown, though ALT has been a widely-used pressure-lowering treatment in the last twenty years. It is not possible to explain the IOP spike by inflammatory reaction since both corticosteroid and non-steroid pretreatment and treatment fail to reduce the immediate IOP elevation, though they do reduce the inflammatory reaction [4, 5, 6, 7]. …”

Section: Introductionmentioning

confidence: 43%

Endothelin-A Receptor Antagonist BQ-485 Protects against Intraocular Pressure Spike Induced by Laser Trabeculoplasty in the Rabbit

Holló¹,

Kóthy²,

Lakatos³

et al. 2002

Ophthalmologica

View full text Add to dashboard Cite

Purpose: We have previously shown in rabbits that the intraocular pressure (IOP) spike caused by argon laser trabeculoplasty (ALT) is associated with an acute endothelin-1 (ET-1) release from the uveal tissue into the aqueous humour. In this study we investigated whether pretreatment with an ET_A receptor antagonist (BQ-485) protects against the pressure spike induced by ALT, in the rabbit model. Methods: Under general anaesthesia, 10 µl of 10^–5M BQ-485 was injected into the anterior chamber of the right eye, and 10 µl of balanced salt solution (BSS) into the contralateral anterior chamber, for 12 pigmented rabbits. Five minutes later ALT (1,000 mW, 0.1 s, 100 spots over 360° focused on the iris pillars) was performed on both eyes of each animal. IOP was measured before the injections (baseline value), and also 30 min afterwards using a Tono-Pen XL tonometer. Immediately after the second IOP measurement aqueous humour was aspirated for measurement of ET-1 concentration. Results: The baseline IOP (mean ± SD) was 8.08 ± 1.73 mm Hg and 7.92 ± 1.78 mm Hg for the right and left eyes, respectively (Duncan test, p > 0.05). At 25 min after ALT the IOP of the BQ-485-pretreated right eyes remained unchanged (7.83 ± 2.44 mm Hg, p > 0.05) but the IOP of the BSS-pretreated left eyes at 30 min increased significantly to 10.67 ± 4.70 mm Hg (p < 0.05 for comparisons both with the corresponding baseline value for the same eye, and with the IOP of the contralateral eye at 30 min). There was no difference in aqueous humour ET-1 concentration between the corresponding right and left eyes (paired t test, p > 0.05). Conclusion: Intracameral BQ-485 pretreatment protected against the ALT-induced acute IOP elevation, but did not influence the laser-induced ET-1 release. This suggests that ET_Areceptor antagonists may potentially have a therapeutic role in the prevention of laser-induced IOP spikes.

show abstract

“…In 15 studies the medication studied was not an antiglaucoma medication (Ascaso 1992; Bucci 1987; Champagne 2015; De Keyser 2017 (identified as a journal article and a trial record); Diestelhorst 1995; Gelfand 1985; Herbort 1992; Herbort 1993; Jinapriya 2014; Kim 1998; Pappas 1985; Realini 2010; Shin 1996; Weinreb 1983; West 1992). Four studies included participants who also received laser peripheral iridotomies and neodymium:YAG laser capsulotomy without separating the results based on the type of laser performed (Chen 2001; Chen 2005; Patel 1998; Stingu 2001).…”

Section: Resultsmentioning

confidence: 99%

“…Early acute IOP elevation is a relatively a common adverse effect of LTP (Barkana 2007; Chen 2001). Studies have shown that transient IOP increase after LTP resulted in loss of vision (Levene 1983) and loss of visual field (Weinreb 1983). Therefore, post-LTP IOP increase is an important and potentially dangerous adverse effect of LTP, especially in a population of people who already have compromised optic nerve function.…”

Section: Discussionmentioning

confidence: 99%

“…One case review of 224 eyes revealed that 3.1% of eyes developed loss of visual acuity or visual field after ALT and 1.8% of eyes required emergency glaucoma surgery to reduce IOP (Levene 1983). Another study reported on a person who experienced substantial IOP increase immediately after ALT and subsequently noticed marked visual field loss within 24 hours of ALT (Weinreb 1983). Finally, one case series reported four occurrences of persistently elevated IOP after SLT of which three eyes required subsequent incisional surgical management of IOP (Harasymowycz 2005).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

Zhang¹,

Weizer

Musch

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Glaucoma is the international leading cause of irreversible blindness. Intraocular pressure (IOP) is the only currently known modifiable risk factor; it can be reduced by medications, incisional surgery, or laser trabeculoplasty (LTP). LTP reduces IOP by 25% to 30% from baseline, but early acute IOP elevation after LTP is a common adverse effect. Most of these IOP elevations are transient, but temporarily elevated IOP may cause further optic nerve damage, worsening of glaucoma requiring additional therapy, and permanent vision loss. Antihypertensive prophylaxis with medications such as acetazolamide, apraclonidine, brimonidine, dipivefrin, pilocarpine, and timolol have been recommended to blunt and treat the postoperative IOP spike and associated pain and discomfort. Conversely, other researchers have observed that early postoperative IOP rise happens regardless of whether people receive perioperative glaucoma medications. It is unclear whether perioperative administration of antiglaucoma medications may be helpful in preventing or reducing the occurrence of postoperative IOP elevation. Objectives To assess the effectiveness of medications administered perioperatively to prevent temporarily increased intraocular pressure (IOP) after laser trabeculoplasty (LTP) in people with open-angle glaucoma (OAG). Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), MEDLINE Ovid (1946 to 18 November 2016), Embase.com (1947 to 18 November 2016), PubMed (1948 to 18 November 2016), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 to 18 November 2016), the metaRegister of Controlled Trials (mRCT) ( www.controlled-trials.com); last searched 17 September 2013, ClinicalTrials.gov (www.clinicaltrials.gov); searched 18 November 2016 and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 18 November 2016. We did not use any date or language restrictions. Selection criteria We included randomized controlled trials (RCTs) in which participants with OAG received LTP. We included trials which compared any antiglaucoma medication with no medication, one type of antiglaucoma medication compared with another type of antiglaucoma medication, or different timings of medication. Data collection and analysis Two review authors independently screened records retrieved by the database searches, assessed the risk of bias, and abstracted data. We graded the certainty of the evidence using GRADE. Main results We included 22 trials that analyzed 2112 participants and identified no ongoing trials. We performed several comparisons of outcomes: one comparison of any antiglaucoma medication versus no medication or placebo, three comparisons of one antiglaucoma medication versus a different antiglaucoma mediation, and one comparison of antiglaucoma medication given before LTP to the same antiglaucoma medication given after LTP. Only one of the included trials used selective laser trabeculopl...

show abstract

Flurbiprofen Pretreatment in Argon Laser Trabeculoplasty for Primary Open-Angle Glaucoma

Cited by 42 publications

References 14 publications

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Endothelin-A Receptor Antagonist BQ-485 Protects against Intraocular Pressure Spike Induced by Laser Trabeculoplasty in the Rabbit

Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

Contact Info

Product

Resources

About